A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell product...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Aakriti, Shere, Amar, Patel, Kunal, Gunawardhana, Nuwan, LiFuentes, Ericka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180301/
https://www.ncbi.nlm.nih.gov/pubmed/32321302
http://dx.doi.org/10.1177/2324709620916358
_version_ 1783525791970099200
author Arora, Aakriti
Shere, Amar
Patel, Kunal
Gunawardhana, Nuwan
LiFuentes, Ericka
author_facet Arora, Aakriti
Shere, Amar
Patel, Kunal
Gunawardhana, Nuwan
LiFuentes, Ericka
author_sort Arora, Aakriti
collection PubMed
description Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell production. Although this mechanism is essential for the management of cancer, it may lead to decreased self-tolerance with an autoimmune reaction toward healthy functioning tissue. One of the less commonly reported and less understood immune-related adverse events includes neuromuscular complications. We present a rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab use for cutaneous squamous cell carcinoma of the cheek.
format Online
Article
Text
id pubmed-7180301
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-71803012020-05-01 A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab Arora, Aakriti Shere, Amar Patel, Kunal Gunawardhana, Nuwan LiFuentes, Ericka J Investig Med High Impact Case Rep Case Report Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 protein (PD-1) receptor and blocks the inhibitory checkpoint interaction between PD-1 and its ligands. This interaction leads to the upregulation of effector T-cells and downregulating regulatory T-cell production. Although this mechanism is essential for the management of cancer, it may lead to decreased self-tolerance with an autoimmune reaction toward healthy functioning tissue. One of the less commonly reported and less understood immune-related adverse events includes neuromuscular complications. We present a rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab use for cutaneous squamous cell carcinoma of the cheek. SAGE Publications 2020-04-22 /pmc/articles/PMC7180301/ /pubmed/32321302 http://dx.doi.org/10.1177/2324709620916358 Text en © 2020 American Federation for Medical Research https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Arora, Aakriti
Shere, Amar
Patel, Kunal
Gunawardhana, Nuwan
LiFuentes, Ericka
A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title_full A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title_fullStr A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title_full_unstemmed A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title_short A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab
title_sort rare case of autoimmune demyelinating polyneuropathy and hydrocephalus secondary to pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180301/
https://www.ncbi.nlm.nih.gov/pubmed/32321302
http://dx.doi.org/10.1177/2324709620916358
work_keys_str_mv AT aroraaakriti ararecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT shereamar ararecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT patelkunal ararecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT gunawardhananuwan ararecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT lifuentesericka ararecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT aroraaakriti rarecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT shereamar rarecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT patelkunal rarecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT gunawardhananuwan rarecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab
AT lifuentesericka rarecaseofautoimmunedemyelinatingpolyneuropathyandhydrocephalussecondarytopembrolizumab

Ejemplares similares